...
首页> 外文期刊>Pharmacogenetics and genomics >Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
【24h】

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

机译:在日本人,高加索人和非裔美国人中,VKORC1和CYP2C9基因多态性对华法林维持剂量的种群内和种群间差异的不同贡献。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, in particular the possible involvement of genetic variability in vitamin K epoxide reductase (VKOR) and CYP2C9. METHODS: Warfarin maintenance dose, unbound plasma S-warfarin concentration [Cu(S)] and INR were determined in 157 Caucasians, 172 Japanese, and 36 African-Americans stably anticoagulated patients. In a subset (n=166), fully carboxylated plasma normal prothrombin levels (NPT) were also measured. Genotyping for seven CYP2C9 (CYP2C9*1 through 6 and *11) and seven VKORC1 variants were performed in 115 Caucasians and 64 Japanese patients and 66 healthy African-Americans. Multivariate analysis was performed to identify covariates associated with warfarin requirement. RESULTS: The relationship between NPT and Cu(S) indicated Japanese are more susceptible to inhibition of NPT production by S-warfarin than the other two populations. VKORC1 1173 C>T had a greater frequency in Japanese (89.1%) than Caucasians (42.2%) and African-Americans (8.6%). CYP2C9 variants with reduced metabolizing ability were less frequent in Japanese compared to the other two populations. The median warfarin dose was significantly higher in Caucasians than Japanese patients (5.5 versus 3.5 mg/day), however, when matched for CYP2C9*1 homozygosity, no difference in dose was observed between VKORC1 genotype-matched groups. Furthermore, VKORC1 1173C>T and CYP2C9 (*2/*3/*11) genotypes, age and weight were identified as independent covariates contributing to interpatient variability in warfarin dosage. CONCLUSIONS: Both VKORC1 and CYP2C9 polymorphisms contribute to inter-population difference in warfarin doses among the three populations, but their contribution to intra-population variability may differ within each population.
机译:目的:研究与抗凝所需的华法林剂量人群差异有关的药代动力学和药效学因素,尤其是遗传变异可能参与维生素K环氧化物还原酶(VKOR)和CYP2C9。方法:测定157名高加索人,172名日本人和36名非裔美国人稳定抗凝患者的华法林维持剂量,血浆S-华法林未结合血浆浓度[Cu(S)]和INR。在一个子集中(n = 166),还测量了完全羧化的血浆正常凝血酶原水平(NPT)。在115位高加索人,64位日本患者和66位健康的非洲裔美国人中进行了7种CYP2C9(CYP2C9 * 1至6和* 11)和7种VKORC1变体的基因分型。进行多变量分析以鉴定与华法令需求相关的协变量。结果:NPT和Cu(S)之间的关系表明,日本人比其他两个人群更容易受到S-华法林抑制NPT产生的影响。 VKORC1 1173 C> T在日本人(89.1%)中的发病率高于白种人(42.2%)和非裔美国人(8.6%)。与其他两个人群相比,日语中具有降低的代谢能力的CYP2C9变体的频率较低。在白种人中,华法林剂量的中位数显着高于日本患者(5.5对3.5 mg /天),但是,当与CYP2C9 * 1纯合性匹配时,在VKORC1基因型匹配组之间未观察到剂量差异。此外,VKORC1 1173C> T和CYP2C9(* 2 / * 3 / * 11)基因型,年龄和体重被确定为有助于患者间华法林剂量差异的独立协变量。结论:VKORC1和CYP2C9多态性均导致华法林剂量在三个人群中的种群间差异,但它们对种群内变异性的贡献在每个人群中可能有所不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号